{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:12Z","timestamp":1792496232353,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.bpg.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T00:32:09Z","timestamp":1407457929000},"page":"665-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Medical treatment of obesity: The past, the present and the future"],"prefix":"10.1016","volume":"28","author":[{"given":"George A.","family":"Bray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"425","key":"10.1016\/j.bpg.2014.07.015_bib1","first-page":"170","article-title":"Recent advances in medicine","volume":"17","author":"Olser","year":"1891","journal-title":"Science"},{"key":"10.1016\/j.bpg.2014.07.015_bib2","series-title":"The battle of the bulge; a history of obesity research","author":"Bray","year":"2007"},{"key":"10.1016\/j.bpg.2014.07.015_bib3","series-title":"A\u00a0discourse on the nature, causes, and cure of corpulency. Illustrated by a remarkable case, read before the Royal Society, November 1757","author":"Flemyng","year":"1760"},{"key":"10.1016\/j.bpg.2014.07.015_bib4","series-title":"A\u00a0discourse concerning the causes and effects of corpulency together with the method for its prevention and cure","author":"Short","year":"1727"},{"issue":"1","key":"10.1016\/j.bpg.2014.07.015_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity Silver Spring"},{"key":"10.1016\/j.bpg.2014.07.015_bib6","article-title":"A\u00a0guide to the practical physician: Shewing, from the most approved authors, both ancient and modern, the truest and safest way of curing all diseases, internal and external, whether by medicine, surgery or diet","author":"Bonet","year":"1684"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib7","first-page":"180","article-title":"On a cretinoid state supervening in adult life in women","volume":"74","author":"Gull","year":"1873","journal-title":"Trans Clin Soc Lond"},{"key":"10.1016\/j.bpg.2014.07.015_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000441-189308000-00001","article-title":"Cases of myxoedema and acromegalia treated with benefit by sheep\u2032s thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of Grave\u2032s disease and acromegalia","volume":"106","author":"Putnam","year":"1893","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.bpg.2014.07.015_bib9","series-title":"Obesity in perspective","first-page":"449","article-title":"Thyroid hormones in the treatment of obesity","volume":"vol. 2","author":"Bray","year":"1976"},{"issue":"2","key":"10.1016\/j.bpg.2014.07.015_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yrtph.2007.03.006","article-title":"Dinitrophenol and obesity: an early twentieth-century regulatory dilemma","volume":"48","author":"Colman","year":"2007","journal-title":"Regul Toxicol Pharmacol"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib11","first-page":"528","article-title":"The central action of betaaminopropylbenzene (benzedrine): clinical observations","volume":"108","author":"Nathanson","year":"1937","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.bpg.2014.07.015_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJM193801202180307","article-title":"Human autonomic pharmacology","volume":"218","author":"Lesses","year":"1938","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.07.015_bib13","first-page":"151","volume":"vol. xii","author":"Kalant","year":"1966"},{"issue":"1","key":"10.1016\/j.bpg.2014.07.015_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0014-2999(78)90269-8","article-title":"Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol","volume":"53","author":"Leibowitz","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpg.2014.07.015_bib15","series-title":"Obesity in perspective. Fogarty International Center series on preventive med","first-page":"409","article-title":"Chemical agents affecting appetite","author":"Heil","year":"1976"},{"key":"10.1016\/j.bpg.2014.07.015_bib16","series-title":"Obesity in perspective","first-page":"429","article-title":"A\u00a0review of experience with fenfluramine","volume":"vol. 2","author":"Burland","year":"1976"},{"issue":"8672","key":"10.1016\/j.bpg.2014.07.015_bib17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(89)91499-2","article-title":"International trial of long-term dexfenfluramine in obesity","volume":"2","author":"Guy-Grand","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bpg.2014.07.015_bib18","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial","volume":"16","author":"Astrup","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"5","key":"10.1016\/j.bpg.2014.07.015_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","article-title":"Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2014.07.015_bib20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"6505","key":"10.1016\/j.bpg.2014.07.015_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bpg.2014.07.015_bib22","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.bpg.2014.07.015_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","article-title":"Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults","volume":"4","author":"Erondu","year":"2006","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib24","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity Silver Spring"},{"issue":"9248","key":"10.1016\/j.bpg.2014.07.015_bib25","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bpg.2014.07.015_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9653","key":"10.1016\/j.bpg.2014.07.015_bib27","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","article-title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Astrup","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"10.1016\/j.bpg.2014.07.015_bib28","doi-asserted-by":"crossref","first-page":"481S","DOI":"10.1002\/j.1550-8528.1995.tb00216.x","article-title":"Efficacy and safety of long-term fluoxetine treatment of obesity\u2013maximizing success","volume":"3","author":"Goldstein","year":"1995","journal-title":"Obes Res"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes Res"},{"issue":"20","key":"10.1016\/j.bpg.2014.07.015_bib30","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/2013.jamainternmed.99","article-title":"Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial","volume":"172","author":"Gadde","year":"2012","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.bpg.2014.07.015_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev"},{"issue":"20","key":"10.1016\/j.bpg.2014.07.015_bib32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"J\u00a0Am Med Assoc"},{"issue":"13","key":"10.1016\/j.bpg.2014.07.015_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"J\u00a0Am Med Assoc"},{"issue":"14","key":"10.1016\/j.bpg.2014.07.015_bib35","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jama.289.14.1826","article-title":"Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study","volume":"289","author":"Ettinger","year":"2003","journal-title":"J\u00a0Am Med Assoc"},{"issue":"2","key":"10.1016\/j.bpg.2014.07.015_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/34.2.154","article-title":"C-terminal octapeptide of cholecystokinin decreases food intake in man","volume":"34","author":"Kissileff","year":"1981","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"10.1016\/j.bpg.2014.07.015_bib37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.bpg.2014.07.015_bib38","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7326\/0003-4819-155-7-201110040-00006","article-title":"Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force","volume":"155","author":"Leblanc","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpg.2014.07.015_bib40","series-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","first-page":"155","author":"Torgerson","year":"2004"},{"issue":"23","key":"10.1016\/j.bpg.2014.07.015_bib41","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"J\u00a0Am Med Assoc"},{"issue":"7631","key":"10.1016\/j.bpg.2014.07.015_bib42","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.bpg.2014.07.015_bib43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/pr.59.2.2","article-title":"Pharmacological treatment of the overweight patient","volume":"59","author":"Bray","year":"2007","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bpg.2014.07.015_bib44","first-page":"346","article-title":"Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink","author":"Douglas","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.bpg.2014.07.015_bib45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000341589","article-title":"An integrated analysis of liver safety data from Orlistat Clinical Trials","volume":"5","author":"Morris","year":"2012","journal-title":"Obes Facts"},{"key":"10.1016\/j.bpg.2014.07.015_bib46","series-title":"A\u00a0guide to obesity and the metabolic syndrome","author":"Bray","year":"2011"},{"issue":"1","key":"10.1016\/j.bpg.2014.07.015_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","article-title":"Serotonergic drugs: effects on appetite expression and use for the treatment of obesity","volume":"67","author":"Halford","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.bpg.2014.07.015_bib48","series-title":"Briefing information: meeting of the Endocrinologic and Metabolic Drugs Advisory Committee","author":"FDA","year":"2012"},{"issue":"3","key":"10.1016\/j.bpg.2014.07.015_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.bpg.2014.07.015_bib50","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A\u00a0one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib51","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity Silver Spring"},{"issue":"2","key":"10.1016\/j.bpg.2014.07.015_bib52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity Silver Spring"},{"issue":"9774","key":"10.1016\/j.bpg.2014.07.015_bib53","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2014.07.015_bib54","series-title":"Briefing information: meeting of the Endocrinologic and Metabolic Drugs Advisory Committee","author":"FDA","year":"2012"},{"key":"10.1016\/j.bpg.2014.07.015_bib55","unstructured":"Brownell K. The learn manual for weight management. Dallas: American Health Publishing Company."},{"issue":"17","key":"10.1016\/j.bpg.2014.07.015_bib56","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","article-title":"The FDA's assessment of two drugs for chronic weight management","volume":"367","author":"Colman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2014.07.015_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.bpg.2014.07.015_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity Silver Spring"},{"issue":"9741","key":"10.1016\/j.bpg.2014.07.015_bib59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2014.07.015_bib60","series-title":"Contrave (Naltrexone SR\/bupropion SR combination) advisory committee briefing document. NDA 200063. Endocrinologic and Metabolic Drugs Advisory Committee meeting","author":"ContraveDocument","year":"2010"},{"issue":"9","key":"10.1016\/j.bpg.2014.07.015_bib61","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/oby.2009.69","article-title":"How physician obesity specialists use drugs to treat obesity","volume":"17","author":"Hendricks","year":"2009","journal-title":"Obesity Silver Spring"},{"key":"10.1016\/j.bpg.2014.07.015_bib62","series-title":"VI-0521 (QNEXA\u00ae) Advisory committee briefing document. NDA 022580. Endocrinologic and Metabolic Drugs Advisory Committee meeting","first-page":"2010","author":"QNEXAdoc","year":"2010"},{"issue":"10","key":"10.1016\/j.bpg.2014.07.015_bib63","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.bpg.2014.07.015_bib64","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/0091270009341651","article-title":"Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist","volume":"49","author":"Addy","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.bpg.2014.07.015_bib65","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","article-title":"Effects on weight reduction and safety of short-term phentermine administration in Korean obese people","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Med J"},{"issue":"13","key":"10.1016\/j.bpg.2014.07.015_bib66","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/CIRCULATIONAHA.111.026567","article-title":"Medical therapy for the patient with obesity","volume":"125","author":"Bray","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bpg.2014.07.015_bib67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/qjmed\/hcm044","article-title":"Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review","volume":"100","author":"Leslie","year":"2007","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.bpg.2014.07.015_bib68","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.bpg.2014.07.015_bib69","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1742-1241.2009.02224.x","article-title":"Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies","volume":"63","author":"Bushe","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"9","key":"10.1016\/j.bpg.2014.07.015_bib70","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity Silver Spring"},{"issue":"1","key":"10.1016\/j.bpg.2014.07.015_bib71","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.bpg.2014.07.015_bib72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"J\u00a0Am Med Assoc"},{"issue":"5","key":"10.1016\/j.bpg.2014.07.015_bib73","doi-asserted-by":"crossref","first-page":"468.e9","DOI":"10.1016\/j.amjmed.2009.11.019","article-title":"Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes","volume":"123","author":"Apovian","year":"2010","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.bpg.2014.07.015_bib74","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"issue":"9701","key":"10.1016\/j.bpg.2014.07.015_bib75","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bpg.2014.07.015_bib76","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A\u00a06-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691814000936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691814000936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T17:44:59Z","timestamp":1565718299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691814000936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1521691814000936"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2014.07.015","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical treatment of obesity: The past, the present and the future","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}